#FSGS
LightNews LightNews
kireports.bsky.social
ACTN4 p.Ile150Met Causes #FSGS With Validation in #Primary #Fibroblasts and Immortalized Podocytes

https://doi.org/10.1016/j.ekir.2025.11.030

#KIRResearchLetter
February 19, 2026 at 6:01 PM
fsgs-fu.bsky.social
💥 Die Dissertation von FSGS-Alumna Jana Maria Weiß ist bei de Gruyter Brill erschienen.

🔗 Mehr Informationen auf unserer Website. Link im Profil!

#publikation #neuerscheinung #fsgs #paulcelan
February 19, 2026 at 10:51 AM
asnpublications.bsky.social
Editors’ Choice 2025: Incidence and Proportion of Primary Focal Segmental Glomerulosclerosis (FSGS) among a Racially and Ethnically Diverse Adult Patient Population between 2010 and 2021

Check out the paper here #ASNCJASN: kidney.pub/CJASN0590
February 17, 2026 at 5:00 PM
dive.style
季節にもよるが1撃40〜50万くらい…って我々はだいぶ正気じゃない遊び方してますよ🤣
たまにバケパでミラコスペチ泊30万がコスパよく見えてくるからFSGSでぶっ壊れた金銭感覚って本当に危ない😌
February 15, 2026 at 12:53 PM
fsgs-fu.bsky.social
❄️ Nach einem produktiven und erfolgreichen Wintersemester verabschieden wir uns nun in die Semesterpause. Wir wünschen euch gute Erholung und freuen uns darauf, euch im Sommersemester 2026 wieder an der #FSGS begrüßen zu dürfen.

#fsgs #literatur #semesterferien #fuberlin
February 13, 2026 at 1:18 PM
transplantation.bsky.social
New hope for recurrent FSGS after kidney transplant: Targeting B cells and plasma cells with rituximab + daratumumab led to remission and improved kidney function in patients who hadn’t responded to standard therapies. #TXPforAll tinyurl.com/3nxrupcs
February 13, 2026 at 1:00 PM
kidneystories.bsky.social
Akebia's Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline - goo.gl/alerts/EiMi22 #GoogleAlerts
Akebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline - TipRanks.com
Akebia Therapeutics ($AKBA) announced an update on their ongoing clinical study. The Phase 2 study titled “A Phase 2 Randomized, Double-Blind, Placebo-Controlled St...
goo.gl
February 11, 2026 at 5:18 PM
ilsedaehn.bsky.social
Proud today to share our latest work showing in vivo evidence that podocyte-derived ET-1 activating GEC ETA drives glomerular injury in FSGS. Congrats Liping Yu & @ubonge.bsky.social and big thanks to all co-authors for this tremendous team effort. #FSGS #nephrology #daehnlab @kidneyint.bsky.social
kidneyint.bsky.social Kidney International @kidneyint.bsky.social · 9d
Podocyte derived endothelin-1 and endothelial cell endothelin A receptors are essential for glomerular injury in mouse models of focal segmental glomerulosclerosis

doi.org/10.1016/j.kint.2026.01.014

#NephSky #MedSky #OpenAccess #FSGS
February 10, 2026 at 10:01 PM
kidneystories.bsky.social
Akebia's Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline - goo.gl/alerts/TPfuWJ #GoogleAlerts
Akebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline - TipRanks.com
Akebia Therapeutics ($AKBA) announced an update on their ongoing clinical study. The Phase 2 study titled “A Phase 2 Randomized, Double-Blind, Placebo-Controlled St...
goo.gl
February 10, 2026 at 9:25 PM
kidneystories.bsky.social
Akebia's Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline - goo.gl/alerts/w5Qx9N #GoogleAlerts
Akebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline - TipRanks.com
Akebia Therapeutics ($AKBA) announced an update on their ongoing clinical study. The Phase 2 study titled “A Phase 2 Randomized, Double-Blind, Placebo-Controlled St...
goo.gl
February 10, 2026 at 7:16 PM
kidneyint.bsky.social
Podocyte derived endothelin-1 and endothelial cell endothelin A receptors are essential for glomerular injury in mouse models of focal segmental glomerulosclerosis

doi.org/10.1016/j.kint.2026.01.014

#NephSky #MedSky #OpenAccess #FSGS
February 10, 2026 at 1:41 PM
kidneyint.bsky.social
Editorial: Special Report
ICD-10 codes for APOL1-mediated kidney disease

doi.org/10.1016/j.kint.2025.09.025

#NephSky #MedSky #chronickidneydisease #FSGS #APOL1 @wakeforestmed.bsky.social
February 9, 2026 at 7:05 PM
epsteinweb.bsky.social
Part 2/2 — HOUSE_OVERSIGHT_025979.jpg
#epsteinweb #houseoversight025979
as of 05-Aug-16 Chart 2: Change** in stress across GFSI sub-components. The biggest moves were declines in stress; led by credit. Notably stress in GBP vol declined post BoE _ 2 180 ee FE eS sen € B02 eS gt i I | | s ages & o of 2-06 ee Gah Se = 7B ° 2 -1.0 _ a 8 _ _ BESLESEREGSES ESS SSS EORESTES EST LERRSRESS ES eS 2-AHUI5IFrI ee TE OSHMA Ss SS rzseeFGtKZZ ee eHGQeCZet gy BLES vse SHEzeszenge el xneSEECSuv se PEPE SSS EvSEaez SE SSE OS OS OS SETAE RB ST BKB BOOB reuse LSU SEC SS BES sS5oHaRB2 22 Ps > enmad eOay Rese ixss sz Sis agen St€NSGRESSZESSEL Fea elSees ec estes aX Psez5RF=2EEgs4re% TeSSS eS FSGS ae tSaSSeSECS ETE ASH28°S 6-553 558 = 2 S p »>*=€ £85250 238 5° Fm ia 2ortege QB = 3 © §22S°E82aG2 6 2 3 ze Ba =z — = ° & 8 uw a id oo oO b= 4 ‘Source: BofA Merrill Lynch Global Research. **Latest as of 05-Aug-16. Change vs 1 week prior (29-Jul-16), ; acd Bankof America > 2 Global Equity Volatility Insights | O9 August 2016 Merrill Lynch HOUSE_OVERSIGHT_025979
February 9, 2026 at 4:03 PM
ibressendorff.bsky.social
Have to opine, though. These are not primary FSGS per KDIGO definition (ie. permeability factor), but rather a combination of genetic FSGS, FSGS of undetermined cause, and perhaps a bit of secondary FSGS (despite thorough work-up).
Doubt that TRPC6i will work in an autoimmune condition…
February 7, 2026 at 1:45 PM
ibressendorff.bsky.social
Tough trial to recruit for, but pretty cool mechanism of action, particularly for TRCP6-FSGS.
February 7, 2026 at 1:41 PM
hswapnil.medsky.social
moving on from IgAN to FSGS: BI 764198 a TRPC6 inhibitor reduces proteinuria in an N = 67 phase 2 RCT

www.thelancet.com/journals/lan...
in @thelancet.com

#NephSky
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
BI 764198 lowered proteinuria and was well tolerated by participants in this trial. This is the first evidence of efficacy with a podocyte-targeted therapy in FSGS. Larger randomised controlled trials...
www.thelancet.com
February 6, 2026 at 11:12 AM
dayaryelle.bsky.social
but I GOT OUT OF THE HOUSE AND SOCIALIZED, DANGIT! 🤣

Oops. Just discovered they discontinued FSGs in 2023. O.o

[4/4]
February 5, 2026 at 9:17 PM
kidneystories.bsky.social
Dimerix to Showcase Phase 3 FSGS Program and Growth Strategy at Euroz Hartleys ... - goo.gl/alerts/XDNVSe #GoogleAlerts
Dimerix to Showcase Phase 3 FSGS Program and Growth Strategy at Euroz Hartleys Healthcare Forum - TipRanks.com
Dimerix Limited ( ($AU:DXB) ) has issued an update. Dimerix Limited announced that CEO and Managing Director Dr Nina Webster will present at the Euroz Hartleys Heal...
goo.gl
February 5, 2026 at 3:32 PM
kidneystories.bsky.social
Apecotrep Shows Promise in Reducing Proteinuria in Primary FSGS in Phase 2 trial - goo.gl/alerts/GuV1Eg #GoogleAlerts
Apecotrep Shows Promise in Reducing Proteinuria in Primary FSGS in Phase 2 trial
In a multicenter, phase 2 trial across 31 centers in 10 countries, apecotrep (BI 764198) reduced proteinuria by 40% over 12 weeks in patients with primary focal segmental glomerulosclerosis (FSGS)....
goo.gl
February 4, 2026 at 11:47 AM
arkanalabs.bsky.social
3/ The presence of nephrotic syndrome and diffuse foot process effacement favors a primary FSGS, while the absence of the later favors secondary FSGS.
February 3, 2026 at 2:32 PM
jessecva.bsky.social
When i was diagnosed with FSGS, one of the medications I was put on first was prednisone, which is a steroid

I was dumb enough to think that all steroids made you ripped. I thought I was walking out the hospital absolutely YOKED
February 3, 2026 at 3:48 AM
nephrotor.bsky.social
Secondary FSGS?!?
February 2, 2026 at 5:05 PM
smtmlfc.bsky.social
Seriously this new approach from Liverpool in the market is mental.

They feed out we're interested in this Dutch lad.

Truth is they were busy fixing a deal with Jacquet and his entourage to make sure that when they bid, they'd be the winner.

FSGs approach has changed and I love it.

Respect. 👇
February 2, 2026 at 12:04 AM
majmundarlab.bsky.social
Sharing a exciting study by Howard Trachtman and colleagues in Lancet demonstrating efficacy of a targeted therapy for genetic FSGS. Exciting development and blueprint for tackling other genetic kidney diseases.

thelancet.com/journals/lancet/article/PIIS0140-6736(25)02255-X/abstract?rss=yes
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
BI 764198 lowered proteinuria and was well tolerated by participants in this trial. This is the first evidence of efficacy with a podocyte-targeted therapy in FSGS. Larger randomised controlled trials...
www.thelancet.com
January 31, 2026 at 8:05 PM
kidneystories.bsky.social
Boehringer announces Phase 2 results in FSGS rare kidney disease - goo.gl/alerts/CKr3LS #GoogleAlerts
goo.gl
January 29, 2026 at 11:55 AM